You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
GTC will sequence samples and help with technical and clinical validation, while C2i will perform AI-based analysis of the data, recruit samples, and perform other clinical trial activities.
The Mayo Clinic Platform, now headed by John Halamka, will lean on Nference for multi-omics analytics to inform biomedical R&D and postmarketing surveillance.
Mayo Clinic Ventures and NTT Venture Capital have invested in the AI software developer to synthesize biomedical data for drug development and precision medicine.
In Nature this week: artificial intelligence system is better at spotting breast cancer than experts and a universal sample multiplexing method for single-cell RNA sequencing.
The Guardian reports GlaxoSmithKline is seeking to bolster its use of artificial intelligence in drug development.
The two companies had worked closely together since Parabricks spun out of the University of Michigan in 2015 and entered the Nvidia accelerator program.
The companies are aiming to use microbial biomarkers to predict the development of precancerous adenomas and carcinomas.
The startup company will use the money to develop its microbial tests and AI-based software for surveillance and prevention of hospital-acquired infections.
After comparing manual methods with the firm's pcr.ai tool in more than 20,000 cases, they found that the use of AI improved test accuracy and reliability.
The companies aim to develop technologies for interpreting cancer genome data, with a focus on linking genetic profiles with treatment responses.
A study of families explores how children transmit SARS-CoV-2, according to the Associated Press.
US Agricultural Research Service scientists have sequenced the genome of the Asian giant hornet.
According to the Economist, pooled testing for COVID-19 could help alleviate strains on testing labs.
In Science this week: MIT researchers outline approach dubbed translatable components regression to predict treatment response among IBD patients.